Avatrombopag: indications, mechanism of action, usage and dosage, side effects, etc.

Indications:

Avatrombopag is a drug used to treat thrombocytopenia in different types of patients, including chronic liver disease-associated thrombocytopenia, cancer chemotherapy-induced thrombocytopenia, and chronic immune thrombocytopenia. Its main function is to increase the number of platelets by promoting platelet production in the bone marrow, thereby reducing the risk of bleeding and helping patients improve their condition and quality of life.

In adults with thrombocytopenia associated with chronic liver disease, avatropopag may be used before elective diagnostic procedures or surgery to reduce the risk of postoperative bleeding. For patients with thrombocytopenia caused by tumor chemotherapy, this drug can increase platelet count, reduce the risk of bleeding, and help ensure the smooth progress of the chemotherapy process. Patients with chronic immune thrombocytopenia can also use avatrombopag to increase platelet count and reduce or prevent bleeding. It is suitable for patients over 18 years of age.

Mechanism of action:

By binding to the platelet production receptor (TPOreceptor), it inhibits the proliferation and differentiation of megakaryocytes in the bone marrow, promotes the production and release of platelets, thereby increasing the number of platelets in the body and reducing the risk of bleeding caused by thrombocytopenia.

Medication method

For patients with chronic immune thrombocytopenia, a starting dose of 20 mg once daily is recommended, with subsequent adjustments in dose or dosing frequency to maintain platelet counts greater than or equal to pan>50×10^9/L, the maximum daily dose is 40mg. For patients with chronic liver disease, the dose is adjusted according to the specific situation, and the platelet count is between 40×10^9/L to 50×10^9/L It is recommended to take 40 mg once a day ; if the platelet count is lower than 40×10^9/LIt is recommended to take 60mg once a day.

Side effects:

When using avatrombopag, some side effects may occur, including allergic reactions, hyponatremia, peripheral edema and malnutrition, as well as more serious thrombosis/Thromboembolism and other complications, as well as other common adverse reactions such as fever, abdominal pain, nausea, headache and fatigue. Patients need to closely monitor their platelet count and clinical symptoms during medication. If they have any severe, persistent or worsening symptoms, they should seek medical advice promptly.

Warnings and precautions:

Before starting avatrombopag, you should discuss your personal and family disease history, allergies, and medications with your doctor in detail to avoid the use of contraindicated medications. Pregnant women may cause harm to their fetus when using this drug. Breast-feeding women should stop breastfeeding while taking the drug. During medication, you should pay close attention to your physical condition. If you experience thromboembolism symptoms such as leg pain, swelling, etc., you should seek medical attention immediately. It should not be used with other drugs without the guidance of a doctor to avoid drug interactions. Regular blood tests are needed to monitor treatment effects and adverse effects.

Drug interactions:

Be aware of possible interactions with anticoagulant drugs, liver enzyme inducers, liver enzyme inhibitors, iron preparations and proton pump inhibitors.

Special groups of people, such as pregnant and lactating women, need to be cautious when using avatrombopag and ensure it is used under the guidance of a doctor to avoid adverse effects.